Search research articles
Contact Us
Filters
Showing results (61-70 of 79) with videos related to
Page
of 8
Sort By:
The Journal of Clinical Investigation
|
December 25, 2019
Genomics of lethal prostate cancer at diagnosis and castration resistance
Joaquin Mateo, George Seed, Claudia Bertan, et al.
Nature Communications
|
May 28, 2025
BH3 mimetics targeting BCL-XL have efficacy in solid tumors with RB1 loss and replication stress
Andreas Varkaris, Keshan Wang, Mannan Nouri, et al.
European Urology
|
September 16, 2022
B7-H3 as a Therapeutic Target in Advanced Prostate Cancer
Christina Guo, Ines Figueiredo, Bora Gurel, et al.
Cancer Cell
|
November 22, 2024
Elucidating acquired PARP inhibitor resistance in advanced prostate cancer
George Seed, Nick Beije, Wei Yuan, et al.
European Urology
|
March 24, 2023
Erratum to "B7-H3 as a Therapeutic Target in Advanced Prostate Cancer" [Eur Urol 2023;83(3):224-38]
Christina Guo, Ines Figueiredo, Bora Gurel, et al.
Cancer Research
|
April 6, 2021
JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer
Alec Paschalis, Jonathan Welti, Antje J Neeb, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 13, 2022
Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer
Adam G Sowalsky, Ines Figueiredo, Rosina T Lis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 27, 2026
Phase I trial of Ipatasertib plus Atezolizumab enhances PI3K/AKT pathway immune responses in solid tumors and refractory glioblastoma
Crescens Tiu, Wing Yau, Diogo Silva, et al.
The Lancet. Oncology
|
December 7, 2019
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
Joaquin Mateo, Nuria Porta, Diletta Bianchini, et al.
European Urology Oncology
|
June 26, 2025
PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular Subtypes
Pasquale Rescigno, Maria Dolores Fenor de la Maza, Holly Tovey, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 79) with videos related to
Sort By:
Page
of 8
The Journal of Clinical Investigation
|
December 25, 2019
Genomics of lethal prostate cancer at diagnosis and castration resistance
Joaquin Mateo, George Seed, Claudia Bertan, et al.
Nature Communications
|
May 28, 2025
BH3 mimetics targeting BCL-XL have efficacy in solid tumors with RB1 loss and replication stress
Andreas Varkaris, Keshan Wang, Mannan Nouri, et al.
European Urology
|
September 16, 2022
B7-H3 as a Therapeutic Target in Advanced Prostate Cancer
Christina Guo, Ines Figueiredo, Bora Gurel, et al.
Cancer Cell
|
November 22, 2024
Elucidating acquired PARP inhibitor resistance in advanced prostate cancer
George Seed, Nick Beije, Wei Yuan, et al.
European Urology
|
March 24, 2023
Erratum to "B7-H3 as a Therapeutic Target in Advanced Prostate Cancer" [Eur Urol 2023;83(3):224-38]
Christina Guo, Ines Figueiredo, Bora Gurel, et al.
Cancer Research
|
April 6, 2021
JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer
Alec Paschalis, Jonathan Welti, Antje J Neeb, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 13, 2022
Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer
Adam G Sowalsky, Ines Figueiredo, Rosina T Lis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 27, 2026
Phase I trial of Ipatasertib plus Atezolizumab enhances PI3K/AKT pathway immune responses in solid tumors and refractory glioblastoma
Crescens Tiu, Wing Yau, Diogo Silva, et al.
The Lancet. Oncology
|
December 7, 2019
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
Joaquin Mateo, Nuria Porta, Diletta Bianchini, et al.
European Urology Oncology
|
June 26, 2025
PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular Subtypes
Pasquale Rescigno, Maria Dolores Fenor de la Maza, Holly Tovey, et al.
Page
of 8